Gedeon Richter gets NICE nod for uterine fibroids drug Ryeqo

Around 4,500 women in the UK will be eligible for treatment with Gedeon Richter's once-daily oral therapy Ryeqo, after NICE backed the GnRH antagonist to treat heavy menstrual bleeding asso

Lilly faces biosimilar rivals to osteoporosis drug Forsteo i...

Allergan and Gedeon Richter set to expand use of bipolar dru...

Allergan and Gedeon Richter are closing in on a new use for their drug Vraylar, after it succeeded in a late-stage study in severe bipolar depression.

Drug price controversies hit pharma's reputation

Pharma’s reputation among patient groups has suffered in 2016, amid ongoing dissatisfaction with the high price of drugs, according to a new survey.

Allergan/Gedeon Richter's uterine fibroids drug succeeds in ...

Allergan and Gedeon Richter's uterine fibroid treatment ulipristal acetate, has succeeded in a phase 3 trial ahead of a planned US filing next year.